Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan

被引：4

作者：

Nakamura, Yasuhiko ^{[1
]}

Kamei, Toshiaki ^{[2
]}

Shinagawa, Masahiro ^{[1
]}

Sakamoto, Yuka ^{[1
]}

Miwa, Ichiro ^{[1
]}

机构：

[1] Yamaguchi Grand Med Ctr, Dept Gynecol, Yamaguchi 7478511, Japan

[2] Yamaguchi Grand Med Ctr, Dept Pathol, Yamaguchi 7478511, Japan

来源：

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH | 2015年 / 41卷 / 05期

关键词：

carboplatin; irinotecan; ovarian cancer; paclitaxel; squamous cell carcinoma; PHASE-II; CANCER; TRIAL;

D O I：

10.1111/jog.12631

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Primary ovarian squamous cell carcinoma is uncommon, and the optimal treatment strategy for this disease has not yet been established. A 71-year-old woman diagnosed with FIGO stage IIb pure ovarian squamous cell carcinoma underwent cytoreductive surgery followed by combination chemotherapy with paclitaxel and carboplatin. After the second treatment course, a recurrent mass grew rapidly, and serum tumor maker levels increased. Monotherapy with weekly irinotecan was then instituted. This second-line chemotherapy was remarkably effective, and the patient subsequently underwent complete interval debulking surgery with a pathological complete response after the third treatment course. Weekly irinotecan is an effective choice for primary ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin.

引用

页码：809 / 812

页数：4